Literature DB >> 2146040

Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD).

G S Francis1, C Benedict, D E Johnstone, P C Kirlin, J Nicklas, C S Liang, S H Kubo, E Rudin-Toretsky, S Yusuf.   

Abstract

Neuroendocrine activation is known to occur in patients with congestive heart failure, but there is uncertainty as to whether this occurs before or after the presence of overt symptoms. In the Studies of Left Ventricular Dysfunction (SOLVD), a multicenter study of patients with ejection fractions of 35% or less, we compared baseline plasma norepinephrine, plasma renin activity, plasma atrial natriuretic factor, and plasma arginine vasopressin in 56 control subjects, 151 patients with left ventricular dysfunction (no overt heart failure), and 81 patients with overt heart failure before randomization. Median values for plasma norepinephrine (p = 0.0001), plasma atrial natriuretic factor (p less than 0.0001), plasma arginine vasopressin (p = 0.006), and plasma renin activity (p = 0.03) were significantly higher in patients with left ventricular dysfunction than in normal control subjects. Neuroendocrine values were highest in patients with overt heart failure. Plasma renin activity was normal in patients with left ventricular dysfunction without heart failure who were not receiving diuretics and was significantly increased (p less than 0.05) in patients on diuretic therapy. We conclude that neuroendocrine activation occurs in patients with left ventricular dysfunction and no heart failure. Neuroendocrine activation is further increased as overt heart failure ensues and diuretics are added to therapy.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2146040     DOI: 10.1161/01.cir.82.5.1724

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  244 in total

Review 1.  Evidence based cardiology: prevention of congestive heart failure and management of asymptomatic left ventricular dysfunction.

Authors:  R S McKelvie; C R Benedict; S Yusuf
Journal:  BMJ       Date:  1999-05-22

Review 2.  Hemodynamic effects of bosentan in patients with chronic heart failure.

Authors:  W Kiowski; G Sütsch; E Oechslin; O Bertel
Journal:  Heart Fail Rev       Date:  2001-12       Impact factor: 4.214

Review 3.  The role of brain natriuretic peptide in population screening.

Authors:  Liselotte N Dyrbye; Margaret M Redfield
Journal:  Heart Fail Rev       Date:  2003-10       Impact factor: 4.214

4.  The role of brain natriuretic peptide in the prediction of cardiac performance in coronary artery bypass grafting.

Authors:  Osman Saribulbul; Ilker Alat; Senol Coskun; Anil Z Apaydin; Tahir Yagdi; Mefkure Kiliccioglu; Emin Alp Alayunt
Journal:  Tex Heart Inst J       Date:  2003

Review 5.  Screening for left ventricular dysfunction: a step too far?

Authors:  T A McDonagh
Journal:  Heart       Date:  2002-10       Impact factor: 5.994

Review 6.  Sudden death in heart failure: underlying electrophysiological mechanisms.

Authors:  Subramaniam C Krishnan; Claudio D Schuger; Sidney Goldstein
Journal:  Heart Fail Rev       Date:  2002-07       Impact factor: 4.214

Review 7.  Emerging therapies for heart failure: renal mechanisms and effects.

Authors:  Amir Kazory; Edward A Ross
Journal:  Heart Fail Rev       Date:  2012-01       Impact factor: 4.214

8.  Role of blood flow in carotid body chemoreflex function in heart failure.

Authors:  Yanfeng Ding; Yu-Long Li; Harold D Schultz
Journal:  J Physiol       Date:  2010-11-15       Impact factor: 5.182

Review 9.  Neurohormonal mechanisms and the role of angiotensin-converting enzyme (ACE) inhibitors in heart failure.

Authors:  A J Coats; S Adamopoulos
Journal:  Cardiovasc Drugs Ther       Date:  1994-10       Impact factor: 3.727

Review 10.  Evaluating presynaptic and postsynaptic innervation in heart failure.

Authors:  Grace P Chen; James H Caldwell
Journal:  Curr Cardiol Rep       Date:  2009-03       Impact factor: 2.931

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.